Attenuation of allergen-evoked nasal responses by local pretreatment with exogenous neuropeptide Y in atopic patients

What Was Tested

This randomized controlled trial paper looks at Neuropeptide Y.

The aim of this study was to determine whether intranasal pretreatment with exogenous NPY could influence the functional responses to subsequent allergen challenge.

Why It Was Studied

Nasal obstruction and rhinorrhea present in allergic rhinitis are at least partly influenced by neuropeptides released from sensory, parasympathetic, and sympathetic nerves.

Neuropeptide Y (NPY) is co-localized with norepinephrine in sympathetic perivascular nerves.

Who Took Part

According to the abstract, 13 patients were involved.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

A randomized double-blind, three-way, crossover, placebo-controlled study was performed in 13 patients with allergic rhinitis.

The number of sneezes and the subjective evaluation of nasal itching obstruction, and rhinorrhea were recorded.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Random assignment meant chance, not the researchers, decided who got Neuropeptide Y and who got the comparison, which limits bias.

Blinding on both sides kept the patients and researchers unaware of who received Neuropeptide Y.

Some patients received a placebo instead of Neuropeptide Y, giving a reference point.

In the crossover set-up each of the patients took both Neuropeptide Y and the comparison in turn, acting as their own control.

Nasal airway resistance was measured by anterior rhinomanometry, and nasal secretions were weighed.

Mean arterial pressure and heart rate were recorded by noninvasive methods.

What Was Measured

The subject headings attached to it are Allergens, Hypersensitivity, Immediate, Nasal Decongestants, Nasal Mucosa, Nasal Provocation Tests, Neuropeptide Y and Oxymetazoline.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Neuropeptide Y in 13 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1996 (The Journal of allergy and clinical immunology), a journal based in United States.

More context: the Neuropeptide Y compound page, all human trials.